EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Palmar Petechiae in a Patient Receiving Ibrutinib for Chronic Lymphocytic Leukemia: A Case Report

Luke Hamilton, Olivia Arriaza, Renat Ahatov, Antonio Jimenez, Brent Kelly

SKIN The Journal of Cutaneous Medicine · 14.07.2026 · 10 (4) · 3253-3258

DOI: 10.25251/z3q4sm13 ↗

Kurz gefasst

Fallbericht in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 14.07.2026. Verfasst von Luke Hamilton und 4 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ibrutinib is an oral Bruton tyrosine kinase (BTK) inhibitor widely used in the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies. Bleeding-related adverse effects are well recognized with this therapy and are thought to result from impaired platelet signaling. Cutaneous findings including petechia and purpura have been described clinically, though the histopathologic features of these eruptions are less frequently discussed. We report a case of a 64-year-old man with CLL receiving long-term ibrutinib therapy who presented with numerous asymptomatic petechial hemorrhages on the palms and a few similar lesions on the soles. The lesions had developed gradually over several months and were increasing in number. Physical examination revealed multiple pinpoint, non-blanching petechial hemorrhages scattered across the bilateral palms. Given the patient's oncologic history and the acral distribution of the lesions, the differential diagnosis included petechiae secondary to ibrutinib therapy, leukocytoclastic vasculitis, embolic phenomena, and angioinvasive infection. A punch biopsy of the left palm demonstrated intraepidermal collections of extravasated erythrocytes, consistent with petechiae, without evidence of vasculitis or infection. These collections were most prominent in the lower epidermis near the dermoepidermal junction. Recognition of this pattern may help distinguish drug-associated petechial eruptions from other causes of palmar petechiae in patients receiving targeted oncologic therapies.

Zitieren

APA

Hamilton, L., Arriaza, O., Ahatov, R., Jimenez, A., & Kelly, B. (2026). Palmar Petechiae in a Patient Receiving Ibrutinib for Chronic Lymphocytic Leukemia: A Case Report. SKIN The Journal of Cutaneous Medicine, 10(4), 3253-3258. https://doi.org/10.25251/z3q4sm13

Vancouver

Hamilton L, Arriaza O, Ahatov R, Jimenez A, Kelly B. Palmar Petechiae in a Patient Receiving Ibrutinib for Chronic Lymphocytic Leukemia: A Case Report. SKIN The Journal of Cutaneous Medicine. 2026;10(4):3253-3258. doi:10.25251/z3q4sm13

BibTeX
@article{Hamilton2026,
  author = {Hamilton, Luke and Arriaza, Olivia and Ahatov, Renat and Jimenez, Antonio and Kelly, Brent},
  title = {Palmar Petechiae in a Patient Receiving Ibrutinib for Chronic Lymphocytic Leukemia: A Case Report},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {4},
  pages = {3253--3258},
  doi = {10.25251/z3q4sm13}
}
Kostenlos starten →